Ricochet is the best place on the internet to discuss the issues of the day, either through commenting on posts or writing your own for our active and dynamic community in a fully moderated environment. In addition, the Ricochet Audio Network offers over 50 original podcasts with new episodes released every day.
The Wall Street Journal Sets Axios Straight on What Delayed the Development of Molnupiravir
Pharmaceutical manufacturer Merck announced today the company is seeking FDA emergency-use authorization for its experimental antiviral treatment for COVID-19, molnupiravir.
On Oct. 1, Merck released a statement that said, “At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of placebo-treated patients.”
